WHO classification of haematolymphoid tumours, fifth edition: myeloid and histiocytic neoplasms
The 2022 World Health Organization classification redefines myeloid cancers, including myelodysplastic neoplasms, acute myeloid leukaemia by genetic type, and the boundaries between them.
Overview
Summary of the fifth-edition WHO classification of myeloid and histiocytic neoplasms, renaming myelodysplastic syndromes as myelodysplastic neoplasms, removing the 20 percent blast threshold for AML with defining genetic abnormalities, and reorganising AML, myeloproliferative neoplasms and secondary myeloid neoplasms around genetics.
The names and definitions on a marrow report (for example MDS with biallelic TP53 inactivation, or AML myelodysplasia-related) come from this document or from the parallel International Consensus Classification.
- Differs in places from the International Consensus Classification published the same year, which can complicate trial eligibility.
Similar pages
not linked directly; found by shared links- Key paperEuropean LeukemiaNet 2020 recommendations for treating chronic myeloid leukaemia
Shares Leukemia, Chronic myeloid leukaemia, accelerated and blast phase.
- TechnologyCD47 and SIRP-alpha blockade
Shares Secondary and therapy-related acute myeloid leukaemia, Higher-risk myelodysplastic syndromes.
- TermHypomethylating agents (azacitidine, decitabine)
Shares Secondary and therapy-related acute myeloid leukaemia, Higher-risk myelodysplastic syndromes.
- TermConditioning regimen (myeloablative, reduced-intensity)
Shares Chronic myeloid leukaemia, accelerated and blast phase, Higher-risk myelodysplastic syndromes.
- TreatmentMagrolimab
Shares Secondary and therapy-related acute myeloid leukaemia, Higher-risk myelodysplastic syndromes.
- TreatmentDecitabine
Shares Secondary and therapy-related acute myeloid leukaemia, Higher-risk myelodysplastic syndromes.
- TermAllogeneic stem cell transplant (allo-SCT)
Shares Chronic myeloid leukaemia, accelerated and blast phase, Higher-risk myelodysplastic syndromes.
- TreatmentCytarabine + anthracycline ('7+3')
Shares Secondary and therapy-related acute myeloid leukaemia, Chronic myeloid leukaemia, accelerated and blast phase.